• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Drops Over 1%; Moderna Reports Downbeat Q3 Results

    11/3/22 2:31:11 PM ET
    $GPRE
    $LNC
    $MRNA
    $NRDS
    Major Chemicals
    Industrials
    Life Insurance
    Finance
    Get the next $GPRE alert in real time by email

    U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday.

    The Dow traded down 0.04% to 32,133.97 while the NASDAQ fell 1.06% to 10,413.75. The S&P 500 also fell, dropping, 0.51% to 3,740.54.

    Also check this: Investor Sentiment Decreases As US Stocks Fall For Second Straight Session


    Leading and Lagging Sectors


    Energy shares gained 2.4% on Wednesday. Leading the sector was strength from VOC Energy Trust (NYSE:VOC) and Green Plains Inc. (NASDAQ:GPRE).


    In trading on Wednesday, information technology shares tumbled by 1.8%.


    Top Headline

     

    Moderna Inc (NASDAQ:MRNA) reported worse-than-expected Q3 results.

     

    • Moderna reported quarterly earnings of $2.53 per share, compared to the $7.70 per share posted a year ago, and also missing the consensus of $3.29 per share. Revenue was $3.36 billion compared to $4.96 million a year ago, also missing the consensus of $3.53 billion.


    Equities Trading UP

     

    • NerdWallet, Inc. (NASDAQ:NRDS) shares shot up 35% to $13.43 after the company reported better-than-expected Q3 EPS and sales results.
    • Shares of Virax Biolabs Group Limited (NASDAQ:VRAX) got a boost, shooting 40% to $2.3499 after the company announced the distribution of a RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit has been launched in markets accepting the CE mark, such as the European Union.
    • Provention Bio, Inc. (NASDAQ:PRVB) shares were also up, gaining 23% to $8.18 after reporting a narrower-than-expected Q3 loss.

     

    Equities Trading DOWN

    • Vapotherm, Inc. (NYSE:VAPO) shares tumbled 38% to $1.30 after the company reported worse-than-expected Q3 results.
    • Shares of Lincoln National Corporation (NYSE:LNC) were down 32% to $35.34 after the company reported worse-than-expected Q3 EPS results.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) was down, falling 37% to $1.91 after the company reported worse-than-expected Q3 sales results and lowered its FY22 sales guidance below analyst estimates.


    Also check out: United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday


    Commodities

    In commodity news, oil traded down 1.2% to $88.89 while gold traded down 1.3% at $1,628.90.


    Silver traded down 1% to $19.395 on Thursday while copper fell 1.2% to $3.4270.


    Euro zone


    European shares closed mostly lower today. The eurozone’s STOXX 600 declined 0.93%, London’s FTSE 100 rose 0.62% while Spain’s IBEX 35 Index fell 1.25%. The German DAX fell 0.95%, French CAC 40 fell 0.54% and Italy’s FTSE MIB Index fell 0.43%.

    The S&P Global/CIPS UK services PMI rose to 48.8 in October versus a preliminary reading of 47.5. The Bank of England raised interest rates by 75 bps to 3% at its November meeting.


    Asia Pacific Markets


    Asian markets closed lower on Thursday, with the Hong Kong’s Hang Seng Index falling 3.08% and China’s Shanghai Composite Index dropping 0.10%.

    The S&P Global India services PMI rose to 55.1 in October versus September's six-month low level of 54.3, while Caixin China general services PMI fell to 48.4 in October from 49.3 in the previous month. The Hong Kong Monetary Authority increased the base rate by 75 basis points to 4.25%. The S&P Global Hong Kong PMI climbed to 49.3 in October compared to 48.0 in the prior month. Australian trade surplus rose to a three-month high of AUD 12.44 billion in September compared to a revised AUD 8.66 billion a month ago.


    Economics

     

    • US-based employers announced 33,843 job cuts during the month of October.
    • US initial jobless claims declined by 1,000 to 217,000 in the week ending October 29th, compared to market estimates of 220,000.
    • Non-farm labor productivity in the US rose by an annualized 0.3% in the third quarter, while unit labor costs in the US nonfarm business sector climbed by 3.5%.
    • The US trade gap increased to a three-month high of $73.3 billion in September versus a revised $65.7 billion gap in August.
    • The S&P Global services PMI rose to 47.8 in October versus a preliminary reading of 46.6.
    • The ISM services PMI declined to 54.4 in October from 56.7 in the previous month.
    • US factory orders increased by 0.3% in September.
    • US natural-gas supplies surged 107 billion cubic feet last week, the EIA said.


    Check out this: Market Volatility Increases Following Powell's Comments


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 99,496,440 cases with around 1,096,710 deaths. India confirmed a total of at least 44,657,140 cases and 530,460 deaths, while France reported over 36,848,600 COVID-19 cases with 157,140 deaths. In total, there were at least 636,560,230 cases of COVID-19 worldwide with more than 6,599,540 deaths.

    Get the next $GPRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GPRE
    $LNC
    $MRNA
    $NRDS

    CompanyDatePrice TargetRatingAnalyst
    Green Plains Inc.
    $GPRE
    2/9/2026$17.00Equal-Weight → Overweight
    Stephens
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Lincoln National Corporation
    $LNC
    12/16/2025Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Green Plains Inc.
    $GPRE
    11/6/2025$10.00Buy → Neutral
    Roth Capital
    Green Plains Inc.
    $GPRE
    10/6/2025$14.00Hold → Buy
    Tudor, Pickering, Holt & Co.
    Lincoln National Corporation
    $LNC
    9/19/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Loneman Ryan P claimed ownership of 17,362 shares (SEC Form 3)

    3 - Green Plains Inc. (0001309402) (Issuer)

    2/10/26 4:51:51 PM ET
    $GPRE
    Major Chemicals
    Industrials

    Former Chief Financial Officer Boggs Philip B covered exercise/tax liability with 23,816 shares and was granted 24,347 shares, increasing direct ownership by 0.66% to 80,892 units (SEC Form 4)

    4 - Green Plains Inc. (0001309402) (Issuer)

    1/23/26 4:18:05 PM ET
    $GPRE
    Major Chemicals
    Industrials

    SVP Operations Collins Trent Lee covered exercise/tax liability with 1,288 shares, decreasing direct ownership by 5% to 26,390 units (SEC Form 4)

    4 - Green Plains Inc. (0001309402) (Issuer)

    1/13/26 4:26:34 PM ET
    $GPRE
    Major Chemicals
    Industrials

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Green Plains Reports Fourth Quarter and Full Year 2025 Financial Results

    Results for the Fourth Quarter 2025 and Future Outlook: Net income attributable to Green Plains of $11.9 million, or EPS of $0.17 per diluted share Adjusted EBITDA of $49.1 million, inclusive of $23.4 million in 45Z production tax credit value net of discounts and other costs Actively marketing 2026 45Z production tax credits Carbon capture fully operational at Central City, Wood River and York, Nebraska facilities Achieved strong utilization in the quarter from the eight operating ethanol plants of 97%, calculated using revised stated capacity Disciplined risk management strategy continues to support first quarter margins and cash flow Green Plains Inc. (NASDAQ:GPRE) (

    2/5/26 6:55:00 AM ET
    $GPRE
    Major Chemicals
    Industrials

    NerdWallet Announces Conference Call to Review 2025 Fourth Quarter and Full-Year Financial Results

    NerdWallet, Inc. (NASDAQ:NRDS), which provides trustworthy financial guidance to consumers and small and mid-sized businesses (SMBs), today announced that it will release its fourth quarter and full-year 2025 financial results on February 25, 2026, and hold a related conference call to discuss the results at 1:30 p.m. Pacific Time the same day. Investors and other interested parties may listen to the call by clicking on the registration link for the webcast or audio conference at https://investors.nerdwallet.com/, NerdWallet's Investor Relations site, where a letter to shareholders will also be posted. A webcast replay will be available on the Investor Relations website for 12 months fo

    2/4/26 6:00:00 PM ET
    $NRDS
    EDP Services
    Technology

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Green Plains upgraded by Stephens with a new price target

    Stephens upgraded Green Plains from Equal-Weight to Overweight and set a new price target of $17.00

    2/9/26 6:55:42 AM ET
    $GPRE
    Major Chemicals
    Industrials

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GPRE
    $LNC
    $MRNA
    $NRDS
    SEC Filings

    View All

    Lincoln National Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LINCOLN NATIONAL CORP (0000059558) (Filer)

    2/12/26 6:05:47 AM ET
    $LNC
    Life Insurance
    Finance

    SEC Form 10-K filed by Green Plains Inc.

    10-K - Green Plains Inc. (0001309402) (Filer)

    2/10/26 4:18:12 PM ET
    $GPRE
    Major Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.

    SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/9/26 10:48:12 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Owen bought $84,340 worth of shares (2,000 units at $42.17), increasing direct ownership by 20% to 12,000 units (SEC Form 4)

    4 - LINCOLN NATIONAL CORP (0000059558) (Issuer)

    11/14/25 7:42:02 AM ET
    $LNC
    Life Insurance
    Finance

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GPRE
    $LNC
    $MRNA
    $NRDS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TZIELD issued to PROVENTION BIO INC

    Submission status for PROVENTION BIO INC's drug TZIELD (ORIG-1) with active ingredient TEPLIZUMAB-MZWV has changed to 'Approval' on 11/17/2022. Application Category: BLA, Application Number: 761183, Application Classification:

    11/21/22 12:03:06 AM ET
    $PRVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Green Plains Inc.

    SC 13G - Green Plains Inc. (0001309402) (Subject)

    11/20/24 1:25:23 PM ET
    $GPRE
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by NerdWallet Inc.

    SC 13G/A - NERDWALLET, INC. (0001625278) (Subject)

    11/14/24 1:28:33 PM ET
    $NRDS
    EDP Services
    Technology

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Leadership Updates

    Live Leadership Updates

    View All

    Green Plains Expands Leadership Team with Ryan Loneman as General Counsel

    Green Plains Inc. (NASDAQ:GPRE) today announced the appointment of Ryan Loneman as General Counsel and Secretary, effective January 26, 2026. In this role, Loneman will lead Green Plains' legal function and serve as a key advisor to senior leadership on corporate governance, strategic transactions, and regulatory matters. "Ryan brings a wealth of legal experience and a strategic perspective that will be invaluable to Green Plains," said Chris Osowski, President and Chief Executive Officer. "His expertise in corporate governance, compliance, and complex transactions positions him well to support our long-term growth strategy." Loneman joins Green Plains from Lindsay Corporation, where he

    1/12/26 9:00:00 AM ET
    $GPRE
    Major Chemicals
    Industrials

    Green Plains Appoints Ann Reis as Chief Financial Officer

    Green Plains Inc. (NASDAQ:GPRE) today announced the appointment of Ann Reis as Chief Financial Officer, effective January 6, 2026. In this role, Reis will lead the finance organization and partner with senior leadership to advance Green Plains long-term strategic and financial objectives. "Ann brings deep financial leadership, industry experience, and operations expertise to drive Green Plains' continued focus on measurement-driven results and operational excellence," said Chris Osowski, President and Chief Executive Officer. "Her collaborative approach to leadership and strategic insight position her well to support our long-term growth strategy." Reis joins Green Plains from Southwest

    1/5/26 9:00:00 AM ET
    $GPRE
    Major Chemicals
    Industrials

    Lincoln Financial Appoints Nilanjan (Neel) Adhya as EVP, Chief AI, Data and Analytics Officer

    Lincoln Financial (NYSE:LNC) today announced the appointment of Nilanjan (Neel) Adhya as Executive Vice President, Chief AI, Data and Analytics Officer (CAIDAO), effective January 9, 2026. In this newly created role, Adhya will advance AI and data as enterprise core capabilities. He will report to Ellen Cooper, Chairman, President and CEO, and will join Lincoln's Senior Management Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204014069/en/Neel Adhya; Source: Lincoln Financial Since 2021, Adhya served as Chief Digital Officer and Global Head of Digital Platforms and Experiences at BlackRock, where he orchestrated cl

    12/4/25 4:15:00 PM ET
    $LNC
    Life Insurance
    Finance

    $GPRE
    $LNC
    $MRNA
    $NRDS
    Financials

    Live finance-specific insights

    View All

    Green Plains Reports Fourth Quarter and Full Year 2025 Financial Results

    Results for the Fourth Quarter 2025 and Future Outlook: Net income attributable to Green Plains of $11.9 million, or EPS of $0.17 per diluted share Adjusted EBITDA of $49.1 million, inclusive of $23.4 million in 45Z production tax credit value net of discounts and other costs Actively marketing 2026 45Z production tax credits Carbon capture fully operational at Central City, Wood River and York, Nebraska facilities Achieved strong utilization in the quarter from the eight operating ethanol plants of 97%, calculated using revised stated capacity Disciplined risk management strategy continues to support first quarter margins and cash flow Green Plains Inc. (NASDAQ:GPRE) (

    2/5/26 6:55:00 AM ET
    $GPRE
    Major Chemicals
    Industrials

    NerdWallet Announces Conference Call to Review 2025 Fourth Quarter and Full-Year Financial Results

    NerdWallet, Inc. (NASDAQ:NRDS), which provides trustworthy financial guidance to consumers and small and mid-sized businesses (SMBs), today announced that it will release its fourth quarter and full-year 2025 financial results on February 25, 2026, and hold a related conference call to discuss the results at 1:30 p.m. Pacific Time the same day. Investors and other interested parties may listen to the call by clicking on the registration link for the webcast or audio conference at https://investors.nerdwallet.com/, NerdWallet's Investor Relations site, where a letter to shareholders will also be posted. A webcast replay will be available on the Investor Relations website for 12 months fo

    2/4/26 6:00:00 PM ET
    $NRDS
    EDP Services
    Technology

    Lincoln National Corporation's Board of Directors Declares Series C and Series D Preferred Stock Dividends

    Lincoln Financial (NYSE:LNC) announced today that the board of directors of Lincoln National Corporation has declared the following preferred stock dividends: Semi-annual dividend of $1,156.25 per share on the corporation's 9.250% Fixed Rate Reset Non-Cumulative Preferred Stock, Series C, $25,000 liquidation preference per share, represented by depositary shares each representing a 1/25th interest in a share of the preferred stock, holders of which will receive $46.25 per share. Quarterly dividend of $562.50 per share on the corporation's 9.000% Non-Cumulative Preferred Stock, Series D, $25,000 liquidation preference per share, represented by depositary shares each representing a 1/1,

    1/30/26 8:00:00 AM ET
    $LNC
    Life Insurance
    Finance